Lilly to present 16 Alzheimer's abstracts at AAIC 2026 in London
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
July 9, 2026 7:30 AM EDTAnalyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data
New data compares the diagnostic performance of P-tau217 blood tests with amyloid positron emission tomography (PET) in cognitively unimpaired Alzheimer's disease
Research spanning diagnostics, long-term treatment, disease biology, and patient-centered outcomes reflects Lilly's 35-year commitment to Alzheimer's disease science
INDIANAPOLIS, July 9, 2026 /PRNewswire/ --Â Eli Lilly and Company (NYSE: LLY) today announced it will... More
